HIP PHARMACOLOGIC APPROACHES will be performed prior to finalization of an individual treatment plan. When choosing among pharmacologic therapies, management should begin with treatments with the least systemic exposure or toxicity. Patients may experience a variety of additional symptoms as a result of the pain and functional limitations arising from OA and/or comorbidities. These include mood disorders, such as depression and anxiety, altered sleep, chronic widespread pain, and impaired